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Abstract
Sphingosine-1-phosphate lyase (SGPL1) insufficiency syndrome (SPLIS) is an autosomal
recessive multi-system disorder, which mainly incorporates steroid-resistant nephrotic
syndrome and primary adrenal insufficiency. Other variable endocrine manifestations are
described. In this study, we aimed to comprehensively annotate the endocrinopathies
associated with pathogenic SGPL1 variants and assess for genotype–phenotype
correlations by retrospectively reviewing the reports of endocrine disease within
our patient cohort and all published cases in the wider literature up to February
2022. Glucocorticoid insufficiency in early childhood is the most common endocrine
manifestation affecting 64% of the 50 patients reported with SPLIS, and a third of these
individuals have additional mineralocorticoid deficiency. While most individuals also
have nephrotic syndrome, SGPL1 variants also account for isolated adrenal insufficiency
at presentation. Primary gonadal insufficiency, manifesting with microphallus and
cryptorchidism, is reported in less than one-third of affected boys, all with concomitant
adrenal disease. Mild primary hypothyroidism affects approximately a third of patients.
There is paucity of data on the impact of SGPL1 deficiency on growth, and pubertal
development, limited by the early and high mortality rate (approximately 50%). There is
no clear genotype–phenotype correlation overall in the syndrome, with variable disease
penetrance within individual kindreds. However, with regards to endocrine phenotype, the
most prevalent disease variant p.R222Q (affecting 22%) is most consistently associated
with isolated glucocorticoid deficiency. To conclude, SPLIS is associated with significant
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multiple endocrine disorders. While endocrinopathy in the syndrome generally presents in
infancy, late-onset disease also occurs. Screening for these is therefore warranted both at
diagnosis and through follow-up.
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Introduction
Sphingosine-1-phosphate lyase insufficiency syndrome
(SPLIS; nephrotic syndrome, type 14; NPHS14; MIM
617575), a multi-systemic disorder of sphingolipid
metabolism first described in 2017, is caused by variants in
SGPL1, in which primary adrenal insufficiency (PAI) and
steroid-resistant nephrotic syndrome (SRNS) necessitating
renal transplantation predominate (1, 2, 3, 4). Additional
clinical features including ichthyosis, progressive
neurological disease, primary hypothyroidism, primary
gonadal insufficiency, lymphopenia and dyslipidaemia
are reported, although not universally present in affected

individuals (Fig. 1). In its most severe form, the condition
results in fetal hydrops. Morbidity is significant and
mortality is high, with 50% fatality, often in the first
decade of childhood and most commonly associated with
end-stage kidney disease and/or sepsis (2, 3, 4, 5, 6, 7, 8, 9,
10).
Sphingolipids form structural components of
mammalian plasma membranes whose roles have been
implicated in signal transduction and cellular recognition
pathways (11). Sphingosine-1-phosphate lyase is a
ubiquitously expressed pyridoxal 5’-phosphate-dependent

Figure 1
Phenotypic spectrum of human disease
characterized by SGPL1 deficiency. A total of 50
patients have been reported, numbers
manifesting each phenotype in parentheses.
*
Including those with adrenal calcifications alone;
†
Four further reports of fetal demise. This figure
was created using modified images from Servier
free medical art (https://smart.servier.com/).
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aldehyde-lyase responsible for the final degradative
step in the sphingolipid pathway, irreversible cleavage
of sphingosine-1-phosphate (S1P) and generation of
2E-hexadecanal and phosphoethanolamine (Fig. 2). S1P
and its upstream sphingolipid intermediates, sphingosine
and ceramide, are bioactive signalling molecules involved
in a variety of molecular programmes and often with
opposing actions (12). Mass spectrometric analysis of
plasma sphingolipid intermediate levels in patients and
conditioned media from patient dermal fibroblasts reveals
variable elevations in upstream sphingolipids when
compared to controls (3, 4). Additionally, breakdown
metabolites 2E-hexadecanal and phosphoethanolamine
are also implicated in important cellular processes
including cytoskeletal reorganization, apoptosis and
oxidative phosphorylation (11, 13, 14, 15). S1P lyase thus
plays a critical role in the dynamicity of the sphingolipid
degradative pathway, and disease related to its deficiency
may be the consequence of upstream accumulation of
sphingolipid intermediates in the affected tissues or
indeed, deficiency of pathway products.
Since the initial descriptions of the syndrome in
2017, several case series and reports have been published,
totalling 50 patients (2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 18, 19,
20, 21). It is clear that the endocrine phenotype within this
rare disease extends beyond PAI, and in contrast to other
disorders of sphingolipid metabolism, SPLIS is associated
with multiple endocrinopathies. In this study, we detail
the endocrine phenotypes associated with the reported
genotypes within our cohort and the wider literature.

e220250

Methods
We retrospectively reviewed clinical data for all children
referred to the Centre for Endocrinology, Queen Mary
University of London, who were diagnosed with
bi-allelic SGPL1 pathogenic variants (approval by the
Outer North East London Research Ethics Committee,
reference number 09/H0701/12), up to February 2022,
totalling 13 patients. We further selected cases in the
literature for inclusion in this study by querying the
National Institutes of Health (NIH)/National Centre for
Biotechnology Information (NCBI) PubMed electronic
database on or before February 2022, for at least any of
the following search terms: ‘SGPL1 mutations’; ‘SGPL1
deficiency’; ‘sphingosine-1-phosphate lyase insufficiency
syndrome’; ‘SPLIS’. Three reviewers independently curated
search results manually to incorporate all published
clinical reports. All individuals reported with bi-allelic
SGPL1 variants were included, totalling 50 patients. Key
endocrine clinical findings reported were assessed against
SGPL1 variant, sex, age of endocrine disease presentation
and ethnicity of patient. Specifically, cases (reports) were
reviewed for details of adrenal disease, including absence/
presence of glucocorticoid/mineralocorticoid deficiency
and presence of pathology on adrenal imaging. Details
of gonadal disease incorporated included clinical features
(microphallus/cryptorchidism/hypospadias) or delayed
puberty, biochemical findings (including gonadotrophins/
sex steroids/AMH) and presence of concomitant adrenal
disease. Details of thyroid disease reviewed included

Figure 2
Overview of sphingolipid metabolism.
Sphingolipid metabolism begins with a common
entry point and exit via a single degradative
pathway. SPT, serine palmitoyl transferase;
KDHSR, ketodihydrosphingosine reductase; CERS,
ceramide synthase; DES, dihydroceramide
desaturase; SMase, sphingomylinease; SMS,
sphingomyelin synthase; CK, ceramide kinase;
C1PP, ceramide-1-phosphate phosphatase;
CDase, ceramidase; SK, sphingosine kinase;
SPPase, sphingosine-1-phosphate phosphatase;
SGPL1, sphingosine-1-phosphate lyase.
https://ec.bioscientifica.com
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the presence of concomitant adrenal/nephrotic disease,
diagnostic TSH and FT4 levels, and pathology identified
on imaging. Where details were not given for each case,
these were designated unknown (U) in the tables of results.
Reports of additional endocrine manifestations were duly
noted.

Results
Clinical phenotype of primary adrenal insufficiency
in SPLIS
Endocrine dysfunction is described in 38 of the 50
patients with SPLIS (Fig. 3). PAI is the most common
endocrine manifestation of the disease and indeed
one of the most predominant clinical features overall.
Thirty-two patients (64% of the 50 patients) presented
with biochemical evidence of PAI, with a male to female
preponderance of approximately 1.7:1 (overall male to
female preponderance in the syndrome being 1.3:1) (Fig.
3 and Table 1) (2, 3, 4, 6, 7, 8, 9, 10, 17, 18, 19, 20, 21). The
median age of PAI presentation among boys was 1 year
(range, 0–6.5 years) and for girls 0.55 years (range, 0.17–
11 years). Most patients presented with PAI in the first 2
years of life (81%; median age, 1 year; range, 0–11 years).
Ten of the children with glucocorticoid deficiency had
additional mineralocorticoid deficiency (31%) (4, 6, 7, 8,
20, 21). The majority had PAI with concomitant nephrotic

Figure 3
Adrenal disease, primary gonadal insufficiency and primary
hypothyroidism are present variably in 38 SPLIS patients with
endocrinopathy.
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syndrome, and in most cases (12 out of 27 patients),
nephrotic syndrome preceded adrenal insufficiency by
a median time of 0.3 years (range, 0.08–10.2 years). For
eight patients, both diagnoses were made at presentation.
In the remaining seven patients, nephrotic syndrome
developed after the PAI diagnosis by a median time of
1.9 years (range, 0.08–12.5 years), highlighting the need
for surveillance of evolving disease. In 13 children where
adrenal imaging was reported, 69% were noted to have
adrenal calcifications (2, 3, 4, 5, 7, 9, 20, 21). In addition,
five further patients had detectable adrenal calcifications
on ultrasonography, although a biochemical diagnosis
of adrenal failure was not provided (2, 3, 5) (Table 1).
Interestingly, adrenal calcification is also a characteristic
feature of lysosomal acid lipase deficiency or Wolman
disease, secondary to saponification of cholesterol and
fatty acid deposits within the adrenal cortex (22). The
mortality rate was just under 50% for patients with PAI
(50% overall for the syndrome), the majority occurring
before the age of 2 years.

Clinical phenotype of primary gonadal insufficiency
in SPLIS
Primary gonadal failure has been reported in nine
boys (Fig. 3 and Table 2), all of whom presented with
bilateral cryptorchidism and seven additionally with
microphallus, suggesting reduced androgen exposure
or action in utero, most likely from the second trimester
onwards. Hypospadias is not a reported clinical feature
to date. Biochemical evaluations revealed raised basal
gonadotrophins (LH and FSH), an exaggerated response
to luteinizing hormone releasing hormone (LHRH)
stimulation, impaired testosterone responsiveness to
human chorionic gonadotrophin (hCG) stimulation and
low anti-Müllerian hormone (AMH) levels. Inhibin B levels
have not been reported in affected individuals. Six of these
affected nine boys presented with biochemical PAI and
hypothyroidism, although all had evidence of adrenal
calcifications on imaging as well as concomitant nephrotic
syndrome (Fig. 3). The majority died in early infancy; the
oldest patient at the age of 12 years. To date, there have
been no reports of pubertal delay in affected girls. Two girls
who have survived into adolescence within our cohort,
commenced menarche and have normal ovarian reserve
as evidenced by sufficient AMH levels (4, 21). One has
bilateral non-neoplastic ovarian calcifications identified
at age 13 years, with no obvious impairment of gonadal
function (21).
This work is licensed under a Creative Commons
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 09/05/2022 05:20:47AM
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6
1
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2
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Y

U
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Y
Y
U
U
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
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Y
Y
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Y
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Y
Y
Y
Y
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U
Y

U
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U
U
U
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Y
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U
Y
U
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U
U
U
N
N
N
N
N
Y
U
N

Y
Y
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U

U
U
N
Y
Y
U
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Calcifications
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U
U
U
U
U
U
U
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U
U
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Calcifications
U
U
Normal
Calcifications
Calcifications
Calcifications
Calcifications

Calcifications
Calcifications
U

U

Calcifications
U
U
Enlarged, calcifications
Calcifications
U

Mineralocorticoid Adrenal findings on
deficiency (Y/N)
imaging

Zhao (10)
Prasad (4)

Janecke (2)

Saygili (18)
Bamborschke (5)
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Janecke (2)
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Linhares (6)
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Maharaj (21)
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Prasad (4)
Prasad (4)
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Settas (17)
Martin (8)
Alrayes (19)
Taylor (9)
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Patients numbered according to position of SGPL1 pathogenic variant.
†
Patients referred to the QMUL cohort.
N, no; NFD, not formally diagnosed (however adrenal calcifications reported); PAI, primary adrenal insufficiency; U, unknown; Y, yes.

c.1513C >T, p.R505*

c.7dup, p.S3Kfs*11
c.7dup, p.S3Kfs*11
c.7dup, p.S3Kfs*11
c.261+1G
c.261+1G
c.395A>G, p.E132G; c.832delA,
p.R278Gfs*17
c.395A > G, p.E132G; c.832delA,
p.R278Gfs*17
c.511A>G, p.N171D
c.518T>A, p.L173Q
c.605C>T, p. S202L; c.1247A>G,
p.Y416C
c.664C>T, p.R222W
c.664C>T, p.R222Q
c.664C>T, p.R222Q
c.664C>T, p.R222Q
c.664C>T, p.R222Q
c.664C>T, p.R222Q
c.664C>T, p.R222Q
c.664C>T, p.R222Q
c.665G>A, p. R222Q
c.665G>A, p.R222Q
c.665G>A: p.R222Q
c.868T>c, p.F290L; c.993C<G,
p.Y331*
c.934delC, p. L312Yfs*30
c.1018C >T, p.R340W
c.1018C >T, p.R340W
c.1018C >T, p.R340W
c.1037G >T, p.S346I
c.1037G >T, p.S346I
c.1049A>G, p.D350G
c.1077del, p.G360Afs*49;
c.1058A>G, p. K353R
c.1079G>T, p.G360V
c.1233delC, p.F411Lfs*56
c.1247A >G, p.Y416C
c.1513C >T, p.R505*

SGPL1 pathogenic variant

Published SPLIS adrenal clinical phenotype (patients 1–37).
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Thyroid disease and SPLIS
Primary hypothyroidism, with mildly raised thyroidstimulating hormone (TSH) and low free-T4, has been
reported in 17 patients (Table 3) (3, 4, 5, 6, 7, 8, 9, 10, 20, 21).
Goitres are not a usual feature of disease (reported in only
one individual) and normal parenchyma is seen on thyroid
ultrasound imaging (3, 4, 5, 6, 7, 8, 9, 10, 21). In most cases,
this was identified in early infancy; however, there are
reports of later diagnoses including one individual aged 12
years (4). The majority of individuals with thyroid disease
(67%) have concomitant PAI and nephrotic syndrome
(Fig. 3). Although mild thyroid dysfunction is reported in
untreated adrenal insufficiency (23), all patients identified
in this cohort required ongoing thyroxine replacement
despite management of their adrenal disease. Similarly,
while urinary loss of thyroid hormones and thyroid
hormone binding proteins can be associated with nephrotic
disease, this is generally compensated by increases in the
free thyroid hormone fraction (24). SPLIS may predispose
to a lower thyroid reserve with hypothyroidism occurring
alongside the onset of nephrotic disease. There are also
individuals, however, who have thyroid disease in the
absence of nephrotic syndrome.
Other endocrine manifestations of SPLIS
Given the high early childhood mortality associated with
SPLIS, limited long-term growth data are available. There is
no clear evidence of intrauterine growth retardation, with
birthweight percentiles ranging from the 1st to the 98th
centile within our cohort and further cases in the literature
(2, 4, 5, 6, 7, 17). No formal assessment of the growth
hormone IGF-1 axis is reported.
Two girls within our cohort have been followed up
longitudinally until adult height was achieved. The first,
born small for gestational age (SGA) with a birthweight SDS
of −2.35, had further evidence of growth failure with a final
height SDS of −3.67 (parent adjusted height SDS of −2.40)
despite IGF-1 levels within normal range. She manifested
PAI and hypothyroidism in the absence of renal disease.
The second, with a birthweight SDS of +1.69, eventually
achieved a parental adjusted height SDS of −3.02. Her
clinical presentation included SRNS at age 9 months, along
with PAI and hypothyroidism. She progressed through
puberty normally and had received two renal transplants
at ages 5 and 12. Another patient first demonstrated signs
of growth restriction when he developed chronic renal

https://ec.bioscientifica.com
https://doi.org/10.1530/EC-22-0250
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failure at 10 months of age. At his last review, at age 8
years, his parental adjusted height SDS was −1.75 having
previously had a birth length SDS of +0.36. His IGF-1 levels
were undetectable on two separate occasions, thought to
be a result of his clinical and nutritional state. Conversely,
another patient, who was born SGA with a birthweight
SDS of −2.64, was reviewed aged 3 years with a height SDS
of +1.43. Interestingly, he harboured the p.R222Q variant
and phenotypically presented with isolated adrenal
disease. Thus, there is no consistent evidence of the impact
of SGPL1 on growth, both in utero or postnatally, and
associated comorbidities may play a role.
Metabolic bone disease is also a reported feature
of SPLIS and at least, three patients in our cohort were
deemed to have tertiary hyperparathyroidism with a
background of chronic renal disease, one necessitating
parathyroidectomy.
Genotype and correlation with
endocrine phenotypes
Bi-allelic SGPL1 mutations include missense, frameshift
and stop-gain variants, which are not ‘domain-centric’
but rather distributed across the entire gene (Fig. 4). The
most prevalent genetic variant in the syndrome is the
single amino acid substitution, p.R222Q, affecting 11
children from different families. This variant is almost
consistently associated with glucocorticoid deficiency
as the only endocrine manifestation. Mineralocorticoid
deficiency is reported in only one individual with this
variant and a further individual is not reported to have any
endocrine phenotype. Furthermore, in five patients with
PAI without associated nephrotic disease, all harboured
the p.R222Q variant, with the exception of one patient
with the p.D350G variant (21). Three out of five of these
patients, however, had other manifestations associated
with the syndrome. The p.R222Q variant has also been
reported with renal disease and there is variability in overall
syndrome phenotype even among kindreds (4). Aside from
the relative consistency in endocrine phenotype seen with
the p.R222Q variant, there are no other clear associations
between endocrinopathy and genotype. Six individuals
reported with all three major endocrinopathies (adrenal,
gonadal and thyroid disease), all with associated nephrotic
disease, had variants which were not confined to the active
pyridoxal-dependent decarboxylase conserved domain of
SGPL1 but were distributed throughout the cytoplasmic
domain (Fig. 4) (4, 5, 7, 9, 10, 20).
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U

U
U

U
U
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U
U
U

U

TPO
antibody
status

Patient numbers correspond to numbers allocated for PAI phenotype in Table 1.
*
Details of results not published; †Patients referred to the QMUL cohort.
N, no; T4, thyroxine; TPO, thyroid peroxidase; TSH, thyroid-stimulating hormone; U, unknown; US, ultrasound; Y, yes.
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Figure 4
Domain topology of reported pathogenic variants in SGPL1 and delineation of associated endocrinopathy. Numbers of patients associated with each
genotype/phenotype are included in parantheses. †Also includes patients with adrenal calcification where biochemical PAI has not been defined.
*
Includes a case of fetal demise.

Discussion
SPLIS has drawn attention to the role of sphingolipids
in the pathogenesis of endocrine disease and the need
for endocrine specialist input in the syndrome. Indeed,
we are mindful that our review of the clinical phenotype
is potentially limited by reporting bias within the 50
published cases and early deaths, therefore, may even
underestimate the prevalence of endocrine disease. While
there is no clear genotype–phenotype correlation overall
in the syndrome, with regards to endocrinopathy, the
most prevalent disease variant p.R222Q is associated
most consistently with an isolated glucocorticoid
deficiency. In the most severe cases of SPLIS, multiendocrine dysfunction is noted in the early postnatal
period. However, late manifestations also indicate scope
for evolving disease. The combination of PAI and SRNS
should certainly alert clinicians to the possibility of SPLIS;
however, individuals can also present with isolated adrenal
disease (4, 17). Mutations in SGPL1 should therefore be
considered as part of the differential diagnosis for PAI of
unknown aetiology, in order to initiate early screening and
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appropriate treatment to reduce morbidity and mortality.
This includes careful clinical review for other features of
the syndrome and biochemical screening, for instance,
for developing nephrotic disease (25). In the absence of
concomitant nephrotic syndrome, other features including
lymphopenia, ichthyosis and neurological disease may
provide clues to the diagnosis (Fig. 1). Neurological disease,
present in approximately half of all patients (including two
PAI patients without nephrotic disease), is varied and can
include microcephaly, neurodevelopmental delay and
regression, sensorineural deafness, peripheral neuropathy
and progressive neurological deterioration (3, 4, 5, 7, 8, 10,
16, 17, 21). Additional endocrinopathy should also raise
suspicion of the syndrome (Fig. 3). Biochemical screening
for endocrinopathy could involve 6–12 monthly evaluation
of adrenal and thyroid function (25). A significant
proportion of patients presenting primarily with nephrotic
disease have had steroid treatment in the initial phase of
their management which may subsequently delay the
diagnosis of adrenal insufficiency. Indeed, clinicians need
to be mindful of the risk of precipitating adrenal crisis with
withdrawal of steroids in SPLIS in those with undiagnosed
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adrenal disease. We find that while there is no overall
significant sex bias in syndrome presentation, there is a
male preponderance among this international cohort
who develop PAI. This is in keeping with findings from a
UK-based PAI cohort, lending to the hypothesis that there
may be sex-based differences in adrenal function rendering
boys more vulnerable (26).
As a third of male patients are reported with gonadal
insufficiency and, given the potential risk for progressive
gonadal failure, close evaluation of puberty and adult
sex steroid production is required. Consideration may be
given to sperm banking for boys where appropriate, in
cases of evolving disease; however, more data are required
on the natural evolution of SPLIS in puberty and effects on
spermatogenesis and fertility. To date, ovarian dysfunction
has not been described although non-neoplastic ovarian
calcifications have been reported. Unlike the fetal testis, the
fetal ovary is not believed to be significantly steroidogenic,
thus the ovaries may ‘escape’, whereas reduced in utero
testicular androgen production/action from the second
trimester onwards result in disorders of sex development
for boys. A similar phenomenon akin to that seen in 46,XX
individuals with STAR variants may occur, where enzyme
deficiency is either compensated for, or girls progress
through puberty appropriately but hypergonadotrophic
hypogonadism ensues thereafter (27, 28).
The pathogenic mechanisms underlying the
endocrine aspects of disease are yet to be fully determined.
Adrenal and gonadal tissue from SPLIS patients have
not been available to study; however, Sgpl1-deficient
mice recapitulate the organ-specific phenotypes seen
in human counterparts. Sgpl1−/− mice have suboptimal
corticosterone production (29) and their adrenals show
disrupted adrenocortical zonation, reduced expression of
steroidogenic enzymes and loss of the typical sub-capsular
clusters of aldosterone synthase (4). Deletion of Sgpl1
abrogates germ cell development in gonads rendering
both male and female Sgpl1−/− mice sterile and attributed
to intra-gonadal accumulation of S1P (30, 31). Testes
exhibit reduced spermatids and Leydig cell numbers, while
increased pre-antral follicle atresia is noted in murine
ovaries (30, 31).
Trophic
ACTH
stimulation
of
NCI-H295R
(adrenocortical carcinoma) cells increases S1P expression
and steroidogenesis (32). Conversely, sphingolipid
intermediates ceramide and sphingosine diminish
steroidogenesis, with sphingosine purported to directly
attenuate the activity of steroidogenic factor 1 (SF-1)
(33). Despite consistent increases in S1P seen in plasma
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derived from patients with SGPL1 deficiency, adrenal
insufficiency manifests. It is possible that on balance,
a greater role is played by the upstream accumulation
of other sphingolipids, ceramide and sphingosine, on
steroidogenesis. S1P exerts its effects through five G
protein coupled receptors (S1PR1-5), and its stimulation of
downstream inositol triphosphate and calcium signalling
can stimulate steroidogenesis (34). The increase in S1P
seen in SPLIS may overwhelm S1P receptors (S1PR)
resulting in their internalisation and degradation, a
phenomenon that has been described in in vitro studies
(35, 36, 37). Understanding the impact of the balance of
sphingolipid intermediates, including the effect of raised
S1P on downstream S1PRs, needs to be further explored in
a steroidogenic model of SGPL1 deficiency.
Patients with S1P lyase deficiency have relatively mild
increases in (TSH). While sphingolipids play an important
role in cell membrane integrity, the sphingolipidcholesterol rich domains in human thyroid follicular cells
do not incorporate the TSH receptor and have no effects
on the TSH/ cAMP cascade thereafter (38). Ceramide
does potentially reduce the transactivation capability
of thyroid transcription factor 1 (TTF-1/NKX2-1) in vitro
(39), which regulates the expression of genes essential
for thyroid hormone biosynthesis (40, 41, 42, 43). While
SGPL1 deficiency in humans does not consistently
translate to growth failure, postnatal growth retardation
is a feature seen in Sgpl1−/− mice (30). Ongoing evaluation
of auxology in all patients is required to assess any impact
of SGPL1 deficiency on growth and it is possible that
comorbidities including renal disease and endocrinopathy
ultimately affect growth, particularly if identified late or
not adequately treated.
The constellation of adrenal, gonadal and thyroid
disease is described in one other non-autoimmuneinherited form of adrenal insufficiency secondary to
mutations in nicotinamide nucleotide transhydrogenase
(NNT), involved in energy transfer in the mitochondrial
respiratory chain (44), although there have now also been
reports of hypothyroidism adding to the phenotype of
adrenal and gonadal insufficiency in MIRAGE syndrome
secondary to gain of function mutations in SAMD9 (45).
Endocrine dysfunction can also be a feature of primary
mitochondrial disorders associated with disruption of
mitochondrial ATP production required for hormone
synthesis and secretion (46). Indeed, perturbation of
mitochondrial dynamics is seen in SPLIS patient dermal
fibroblasts with subsequent impact on steroidogenesis
(47). Mitochondrial disruption may account for the
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endocrine phenotype in SPLIS, setting it apart from the
other disorders of sphingolipid metabolism.
There are limited reports of endocrinopathy in other
sphingolipid diseases, which are in the main lysosomal
storage disorders (48). Fabry disease results in systemic
accumulation of globotriaosylceramide and has been
associated with subclinical hypothyroidism (49, 50).
In a study of 18 Fabry patients, suboptimal cortisol
concentrations and higher ACTH levels when compared
with controls were reported although only one patient had
proven PAI after cosyntropin stimulation and one patient
was diagnosed with hypergonadotrophic hypogonadism
(50). Interestingly, increased S1P has been implicated
in the pathophysiology of Fabry disease (51). The
endocrinopathy seen in SPLIS does raise the question as to
whether clinicians need to be more mindful of endocrine
disease in the sphingolipidoses.
There is currently no single curative therapy for
this multi-systemic disorder. Renal transplantation
for the SRNS and hormone replacement for endocrine
dysfunction remain the mainstay of treatment. Exogenous
administration of pyridoxine (Vitamin B6), a co-factor
for S1P lyase, demonstrates some improvements in
immunological profiles and absolute lymphocyte counts,
for patients with the p.R222Q genotype, but does not avert
end organ damage or rapidity of disease progression (10).
More recently, adenoviral gene transfer of human SGPL1
to newborn Sgpl1 null mice prolonged survival and averted
development of anaemia, nephropathy, neurological
compromise and lipid dyshomeostasis (29). Gene transfer
did not, however, restore corticosterone production (29).

Conclusion
Careful phenotyping of the surviving SPLIS cohort and
new patients is critical in understanding the role that
SGPL1 plays in endocrine function, evolving disease
and response to future treatment. Furthermore, the
sphingolipid pathway is a therapeutic target in oncology
and autoimmune disease (12) and further study of the
effects of disrupted sphingolipid homeostasis in SPLIS
will also inform on the potential endocrine impact of
therapeutically targeting the pathway in other conditions.
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